"Krankenhaus der Schwerpunktversorgung mit rund 600 Betten und 15 Fachabteilungen. Notaufnahme an 365 Tagen rund um die Uhr geöffnet. Schwerpunkte unter anderem: Geburtshilfe, Gynäkologie, Gefäßmedizin, Kardiologie, Onkologie, HNO-Heilkunde, Orthopädie, Pneumologie, Chirurgie."

During the past decade, Marienkrankenhaus Hamburg conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 6 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Marienkrankenhaus Hamburg" #1 sponsor was "Abbott Medical Devices" with 3 trials, followed by "Edwards Lifesciences" with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "LMU Klinikum" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Marienkrankenhaus Hamburg" #1 collaborator was "Abbott" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator, "Australia New Zealand Gynaecological Oncology Group" with 1 trials as a collaborator and "Central European Cooperative Oncology Group" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Marienkrankenhaus Hamburg" are "Mitral Regurgitation" (3 trials), "Breast Cancer" (2 trials), "Mitral Valve Regurgitation" (2 trials), "Tricuspid Valve Regurgitation" (2 trials) and "Asphyxia Neonatorum" (1 trials). Many other conditions were trialed in "Marienkrankenhaus Hamburg" in a lesser frequency.

Most popular intervention types in "Marienkrankenhaus Hamburg" are "Drug" (14 trials), "Device" (9 trials), "Biological" (3 trials), "Other" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (4 trials), "Leucovorin" (3 trials), "Oxaliplatin" (2 trials), "5-FU" (1 trials) and "5-Fluorouracil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Marienkrankenhaus Hamburg" are 22 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Marienkrankenhaus Hamburg". undefined are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Marienkrankenhaus Hamburg, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Marienkrankenhaus Hamburg, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".